+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Actively Recruiting

Phase 2
Age: 18Years - 75Years
All Genders
ID05757336

Phase II Study of Sintilimab and Bevacizumab with Gemcitabine and Albumin-bound Paclitaxel as First Treatment for Unresectable Gallbladder Cancer

Led by Lu Wang, MD, PhD · Updated on 2023-03-07

50

Participants Needed

1

Research Sites

104 weeks

Total Duration

AI-Summary

What This Trial Is About

Researchers are evaluating a combination treatment using Gemcitabine, Nab-paclitaxel, Sintilimab, and Bevacizumab for patients with initially unresectable gallbladder cancer. This phase II, single-center study aims to assess the objective response rate, safety, disease control rate, disease-free survival, overall survival, and the possibility of successful surgical removal of primary tumors. The study uses Simons two-stage design with an initial 15 patients, expanding to 45 if sufficient response is seen. The treatment involves cycles every three weeks, with two dose regimens of Gemcitabine and Nab-paclitaxel, combined with fixed doses of Sintilimab and Bevacizumab. Patients receive these drugs intravenously and continue treatment until their cancer becomes operable, disease progresses, intolerable side effects occur, or they choose to stop. Evaluations occur every nine weeks to decide on surgery or continuation. Participants will have regular safety assessments of side effects using CTCAE 5.0 criteria and monitoring visits every 90 days after treatment ends until death, loss to follow-up, or study completion. Researchers will track tumor response, disease progression, survival outcomes, and the rate of successful surgeries. The total participation duration varies depending on individual treatment response and follow-up status.

CONDITIONS

Brief Title

Combination of Gemcitabine, Albumin-paclitaxel , Sintilimab and Bevacizumab in Unresectable Gallbladder Cancer

Research Team

L

Lu Wang

Not the Right Trial for You?

Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.

Already have an account? Log in here